Antibody based Therapeutics Research Fields
Research Fields | Goals | Details |
|---|---|---|
Discovery | Discovery of antibodies against diverse targets | Our research focuses on identifying tumor microenvironment based targets and discovering antibodies using phage display aiming to induce anti-tumor effects through signal blockade and immune activation. |
Multispecifics | Development of antibodies targeting multiple antigens simultaneously | Our research focuses on designing and developing multispecific antibodies (bispecific, biparatopic, and trispecific) that simultaneously target multiple antigens to overcome complex disease mechanisms enabling modulation of the tumor microenvironment, activation of immune cells and simultaneous inhibition of signaling pathways. |
Immunomodulation | Development of immune checkpoint inhibitors and bispecific antibodies | Our research aims to develop proprietary immune checkpoint inhibitors targeting specific immune cell sub-types to enhance immune activation. We establish intellectual property through sequence and patent analyses and subsequently engineer these antibodies into bispecific formats. Antibodies are produced using CHO-based expression systems and evaluated for functional efficacy. We also investigate diverse immune checkpoint targets within the tumor microenvironment to design subtype-specific targeting strategies for therapeutic development. |
New Modality | Engineering of antibody-based Omomyc and asymmetric siRNA therapeutics | Our goal is to improve the delivery of Omomyc and asymmetric siRNA to tumors by conjugating them with antibodies. This approach is expected to increase the specificity of drug delivery reducing off-target effects and inducing apoptosis of cancer cells by targeting MYC protein and other cancer-related genes within the tumor microenvironment. |
IFN-β based Therapeutics | Development of immunocytokines | Our research focuses on developing IFN-β–based immunocytokines by conjugating cytokines to antibodies for tumor-specific delivery while employing masking strategies to minimize systemic toxicity and maximize immune activation. |